Aerovate Therapeutics (AVTE)
(Real Time Quote from BATS)
$1.92 USD
-0.02 (-1.03%)
Updated Sep 6, 2024 03:44 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Aerovate Therapeutics, Inc. (AVTE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.20 | $27.00 | $2.00 | 271.13% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Aerovate Therapeutics, Inc. comes to $7.20. The forecasts range from a low of $2.00 to a high of $27.00. The average price target represents an increase of 271.13% from the last closing price of $1.94.
Analyst Price Targets (5 )
Broker Rating
Aerovate Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 3.00 a month ago based on six recommendations.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/AVTE.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 6 | 6 | 6 | 7 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.00 | 3.00 | 3.00 | 3.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/18/2024 | Evercore Partners | Liisa A Bayko | Not Available | Hold |
6/18/2024 | Wells Fargo Securities | Tiago Fauth | Strong Buy | Hold |
6/17/2024 | Not Identified | Not Identified | Strong Buy | Hold |
6/17/2024 | BTIG | Julian Harrison | Strong Buy | Hold |
6/17/2024 | Wedbush Securities | Laura Chico | Strong Buy | Hold |
6/17/2024 | Guggenheim Securities | Vamil Divan | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 6 |
Average Target Price | $7.20 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.59 |
AVTE FAQs
Aerovate Therapeutics, Inc. (AVTE) currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 6 brokerage firms.
The average price target for Aerovate Therapeutics, Inc. (AVTE) is $7.20. The current on short-term price targets is based on 2 reports.
The forecasts for Aerovate Therapeutics, Inc. (AVTE) range from a low of $2 to a high of $27. The average price target represents a increase of $271.13 from the last closing price of $1.94.
The current UPSIDE for Aerovate Therapeutics, Inc. (AVTE) is 271.13%
Based on short-term price targets offered by five analysts, the average price target for Aerovate Therapeutics, Inc. comes to $7.20. The forecasts range from a low of $2.00 to a high of $27.00. The average price target represents an increase of 271.13% from the last closing price of $1.94.